Last reviewed · How we verify

NCT05023746

Clinical Evaluation of Genetron Lung Cancer Panel in Non-small Cell Lung Cancer Patients

Completed Last updated 1 September 2021
What this trial tests

trial testing Genetron lung cancer panel in Non-Small Cell Lung Cancer in 1,052 participants. Completed in 17 September 2019.

Timeline
30 August 2018
Primary endpoint
9 September 2019
17 September 2019

Quick facts

Lead sponsorGenetron Health
StatusCompleted
Study typeOBSERVATIONAL
Enrollment1,052
Start date30 August 2018
Primary completion9 September 2019
Estimated completion17 September 2019
Sites4 locations across China

Drugs / interventions tested

Conditions studied

Sponsor

Genetron Health

Who can join

Eligibility, any sex, with Non-Small Cell Lung Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this trail is to evaluate the performance of Genetron lung cancer panel in non-small cell lung cancer patients using semiconductor sequencing method.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Non-Small Cell Lung Cancer

Currently open trials in the same condition.

Other Genetron Health trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05023746.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing